Ono Pharmaceutical (4528.T) announced that it has submitted an application for the manufacturing and marketing approval of ripretinib or DCC-2618, developed by Deciphera Pharmaceuticals, for the indication of gastrointestinal stromal tumor that has progressed following cancer chemotherapy. The application is based on the results of the INVICTUS study, a global Phase 3 clinical study.
Deciphera, a member of Ono Pharmaceutical Co., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines and providing hope to people living with cancer, neurologic and autoimmune disease.
Shares of Ono Pharma are trading at 2,476 yen, up 0.61%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.